Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study

Five-year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: the IM-UNITI trial

(2021) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

(2021) Dan Turner et al.   GASTROENTEROLOGY

Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

(2021) Sailish Honap et al.   DIGESTIVE DISEASES AND SCIENCES

Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry

(2021) María Chaparro et al.   Journal of Crohns & Colitis

Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study

(2021) Mathurin Fumery et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

One-year effectiveness and safety of ustekinumab in Ulcerative Colitis: a multicenter real-world study from Italy

(2021) Michele Francesco Chiappetta et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

(2020) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study

(2020) Aurélien Amiot et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-Analysis

(2020) Clara Yzet et al.   Clinical Gastroenterology and Hepatology

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

(2020) William J Sandborn et al.   INFLAMMATORY BOWEL DISEASES

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

(2019) Subrata Ghosh et al.   DRUG SAFETY

The impact of smoking and smoking cessation on disease outcomes in ulcerative colitis: a nationwide population-based study

(2019) Jonathan Blackwell et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2019) Bruce E. Sands et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis

(2016) N. To et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Demyelination in a patient receiving ustekinumab for refractory Crohn's disease: Figure 1

(2014) Yaeesh Badat et al.   Journal of Crohns & Colitis

Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

(2012) Christina Ha et al.   Clinical Gastroenterology and Hepatology

Tumor necrosis factor-α antagonists and neuropathy

(2007) Joerg-Patrick Stübgen   MUSCLE & NERVE